Andreev D, Pampulov L
Vutr Boles. 1975;14(3):110-7.
The investigation is realized with 50 diabetics, considered suitable for oral therapy that revealed excellent or satisfactory effect from the Glybenclamide treatment (GCL), applied separately or in combination with butyl biguanide. GCL was established to give far better results than the rest oral antidabetic drugs, permitting a better metabolic syndrome compensation. GCL effect is more manifested than that of tolbutamide. The better therapeutic effect of GCL is obvious as compared with chloropropamide and butyl biguanide, but not so well manifested as with tolbutamide. The therapeutic GCL effect is better in almost all followed up ages, the most advanced incld., which is not cogent for the rest of the oral preparations. Side effects and severe hypoglycemic incidence, reported by other authors, were not observed during the investigation.
该研究对50名糖尿病患者进行，这些患者被认为适合口服治疗，他们单独使用格列本脲（GCL）或与丁双胍联合使用时，格列本脲治疗显示出极佳或令人满意的效果。已证实GCL比其他口服抗糖尿病药物效果好得多，能更好地代偿代谢综合征。GCL的效果比甲苯磺丁脲更明显。与氯磺丙脲和丁双胍相比，GCL的治疗效果更好，但不如甲苯磺丁脲那么显著。在几乎所有随访年龄段中，GCL的治疗效果都更好，包括年龄最大的患者，而其他口服制剂则没有这么有说服力。在研究过程中未观察到其他作者报道的副作用和严重低血糖发生率。
